Rein Therapeutics (RNTX) investor relations material

Executive summary

• Focused on developing therapies for orphan pulmonary and fibrosis indications, with LTI-03 as the lead candidate in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF); surpassed 25% enrollment in the global Phase 2 RENEW trial, with interim data expected in the second half of 2026.

• LTI-01 development paused indefinitely to prioritize LTI-03; LTI-01 has completed Phase 1b and 2a trials for loculated pleural effusions and holds Orphan Drug and Fast Track designations.

• Peer-reviewed publication in Nature Communications validated LTI-03's safety and efficacy in reducing lung scarring markers in IPF patients.

• No revenue from product sales; company remains in clinical development stage.

Financial highlights

• Net loss was $6.4 million for Q2 2026, compared to $6.8 million in Q2 2025.

• Net loss for the six months ended June 30, 2026 was $12.2 million, compared to $12.3 million for the same period in 2025.

• Cash, cash equivalents, and investments totaled $43.6 million as of June 30, 2026.

• Completed a public offering in May 2026, raising $57.5 million in gross proceeds, including full exercise of the over-allotment option.

• Weighted average shares outstanding increased to 67.1 million from 24.2 million year-over-year due to equity offerings.

Outlook and guidance

• Current cash and investments expected to fund operations into Q1 2028 and complete the Phase 2 RENEW trial of LTI-03.

• Enrollment in the Phase 2 RENEW trial is ahead of schedule, with interim data anticipated in Q4 2026.

• Ongoing evaluation of additional financing options and potential business development activities.